RNAC (Cartesian Therapeutics) Debt-to-Asset : 0.20 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RNAC Cartesian Therapeutics Inc RNAC
24 GF Score
Price $10.58
GF Value $0.29
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Cartesian Therapeutics Debt-to-Asset?

Cartesian Therapeutics RNAC +5.12% 24 Debt-to-Asset is 0.20 as of Jun. 2026. GuruFocus rates RNAC with a GF Score™ of 24/100 and a GF Value™ of $0.29 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Cartesian Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $4.20 Mil. Cartesian Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $59.66 Mil. Cartesian Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $318.63 Mil. Cartesian Therapeutics's debt to asset for the quarter that ended in Jun. 2026 was 0.20.

Cartesian Therapeutics  (NAS:RNAC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Cartesian Therapeutics Debt-to-Asset Related Terms

Cartesian Therapeutics Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Cartesian Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cartesian Therapeutics Debt-to-Asset Chart

Cartesian Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.23 0.04 0.03 0.04

Cartesian Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.04 0.04 0.20

RNAC vs CNXU, GALT, SRZN: Debt-to-Asset Comparison

For the Biotechnology subindustry, Cartesian Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cartesian Therapeutics Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cartesian Therapeutics's Debt-to-Asset falls into.


RNAC
24GF Score
Cartesian Therapeutics Inc RNAC
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cartesian Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cartesian Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(4.151 + 8.525) / 296.411
=0.04

Cartesian Therapeutics's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(4.197 + 59.656) / 318.628
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.20 mean?
Cartesian Therapeutics (RNAC) has a Debt-to-Asset of 0.20 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Cartesian Therapeutics and its competitors.
Is Cartesian Therapeutics' Debt-to-Asset too high?
Cartesian Therapeutics' current Debt-to-Asset is 0.20. Overall, Cartesian Therapeutics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cartesian Therapeutics' Debt-to-Asset compare to CNXU and GALT?
Cartesian Therapeutics' Debt-to-Asset of 0.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Cartesian Therapeutics and its competitors. Cartesian Therapeutics's current Debt-to-Asset is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cartesian Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cartesian Therapeutics (RNAC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $10.58 — trading 3548.3% above its estimated fair value. The current Debt-to-Asset is 0.20. Cartesian Therapeutics' overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Cartesian Therapeutics (RNAC), the current Debt-to-Asset is 0.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cartesian Therapeutics (RNAC) Overvalued in 2026?

Based on GuruFocus' analysis, Cartesian Therapeutics stock appears to be overvalued. The current stock price of $10.58 is trading 3548.3% above its estimated GF Value™ of $0.29. GuruFocus considers Cartesian Therapeutics to be Significantly Overvalued.

Key valuation signals for RNAC:

  • Debt-to-Asset: 0.20
  • GF Value™: $0.29 vs. price of $10.58 (3548.3% above fair value)
  • GF Score™: 24/100 with 5 warning signs

No single metric tells the full story. See the RNAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cartesian Therapeutics Business Description

Other Exchanges 1S70:Germany
Address 7495 New Horizon Way, Frederick, MD, USA, 21703
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
24GF Score

Get the complete analysis for RNAC

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.58
Price
$0.29
GF Value